---
title: "Triglyceride Omega-3 vs Ethyl Ester vs Krill Oil Drug Interactions, CYP450 Pathways & Contraindications | Nutrition Research Labs"
source_url: "https://nutritionresearchlabs.com/interactions/omega-3-triglyceride-vs-ethyl-ester-krill-oil-totox-audit"
canonical_url: "https://nutritionresearchlabs.com/interactions/omega-3-triglyceride-vs-ethyl-ester-krill-oil-totox-audit"
retrieved_by: "AnswerRail Edge Engine v1.1.0-parity-v20 (https://answerrail.com)"
provenance: "Compiled for deterministic AI retrieval by AnswerRail Edge (RFC 9110 / RFC 9421)"
description: "Clinical interaction analysis for Triglyceride Omega-3 vs Ethyl Ester vs Krill Oil. Screen hepatic CYP3A4/CYP2D6 enzyme risks, contraindications with prescription medications, and adverse event warnings."
rfc_compliance: "RFC 9110 / RFC 9309 / RFC 9421"
version: "1.1.0"
release_version: "v1.1.0-parity-v20"
signing_kid: "ar_ed25519_2026_k1"
jwks_uri: "https://answerrail.com/.well-known/http-message-signatures-directory"
edge_network: "Cloudflare Workers Anycast (330+ Global PoPs)"
verified_latency: "<15ms (Warm Edge Cache HIT) / 80-250ms (Cold AST Compile)"
---

> **Canonical Source:** [https://nutritionresearchlabs.com/interactions/omega-3-triglyceride-vs-ethyl-ester-krill-oil-totox-audit](https://nutritionresearchlabs.com/interactions/omega-3-triglyceride-vs-ethyl-ester-krill-oil-totox-audit)
>
> *Clinical interaction analysis for Triglyceride Omega-3 vs Ethyl Ester vs Krill Oil. Screen hepatic CYP3A4/CYP2D6 enzyme risks, contraindications with prescription medications, and adverse event warnings.*

## Absolute Clinical Contraindications

- Concurrent high-dose antithrombotic or anticoagulant therapy without INR monitoring
- Fish or shellfish allergy (for krill)
- Upcoming scheduled major surgery

## Reported Clinical Adverse Events

- Fishy burps or reflux (sign of high oxidation or EE formulation)
- Mild loose stools at >4g doses
- Increased bleeding time

## Hepatic Cytochrome P450 (CYP) & Transporter Pathways

Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:

- **CYP3A4 Substrate / Inhibitor:** Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
- **Gastrointestinal Transit Modulation:** GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
- **Pharmacokinetic Half-Life Clearance:** Systemic clearance requires approximately 5 elimination half-lives (RBC membrane incorporation half-life: 4 - 8 weeks).

## Protocol Audit Links for Triglyceride Omega-3 vs Ethyl Ester vs Krill Oil

---

## 🏛️ AI Ingestion & Edge Optimization Provenance
This sovereign authority subpage is compiled and delivered across 330+ Cloudflare Anycast edge locations by [AnswerRail](https://answerrail.com) for [https://nutritionresearchlabs.com/interactions/omega-3-triglyceride-vs-ethyl-ester-krill-oil-totox-audit](https://nutritionresearchlabs.com/interactions/omega-3-triglyceride-vs-ethyl-ester-krill-oil-totox-audit).